Bringing the whole ecosystem together
SwedenBIO is the national trade organization for life sciences in Sweden.
Our member companies develop biotechnology, diagnostics, pharmaceuticals and medical devices or are experts in business development, IP and law, among others. We also bring together financiers, incubators, science parks, regional investment promoters and many more.
What our members have in common is that they are instrumental in developing medical innovations that improve human health in Sweden and the world, whether they are individual entrepreneurs or large global life science companies.
SwedenBIO is a non-profit membership organization. The highest decision-making body is the general assembly, which also appoints the organization’s board of directors. The daily operations are run by a secretariat located in central Stockholm.
SwedenBIO was founded in 2002 by the CEOs of seven leading Swedish life science companies: Amersham Biosciences (now Cytiva), Active Biotech, Biovitrum (now SOBI), KaroBIO, Medivir, Melacure Therapeutics and Pharmacia Diagnostics (now Thermo Fisher).
We own and organise the Nordic partnering conference Nordic Life Science Days, which first took place in 2013.
Our members
Our vision and mission
SwedenBIO’s vision is a nationally viable and internationally competitive life science industry in Sweden.
Our mission is to strengthen the competitiveness of the Swedish life science industry. In the face of global competition, Sweden needs to offer attractive conditions for life science companies to grow and develop here, as well as for international companies to choose to locate operations in our country.
Our objectives
Our goals for the business are that SwedenBIO will:
- Building strong business networks.
- Disseminating facts and knowledge.
- Give the industry a strong voice in the public debate.
Our values
Reliable: We consistently deliver on our commitments, fulfill expectations and are professionally accountable for our promises.
Agile: We are flexible and responsive to change while adapting to new ideas and innovative solutions
Diverse: We strive to build an inclusive ecosystem and recognise that our strength lies in the combined expertise of our diverse network to create impact.
Accessible: We engage in thoughtful conversations, show openness and proactively reach out to our community in a relaxed atmosphere.
History of SwedenBIO
SwedenBIO is founded
SwedenBIO was founded in 2002 by the CEOs of seven leading Swedish life science companies: Amersham Biosciences (now GE Healthcare), Active Biotech, Biovitrum (now SOBI), KaroBIO, Medivir, Melacure Therapeutics and Pharmacia Diagnostics (now Thermofisher).
SwedenBIO offers advice for SMEs on EU applications
A service that is now run together with several organizations around the country, with funding from Tillväxtverket and Vinnova. SwedenBIO provides life science-specific expertise and advice on EU applications.
First pipeline report released
SwedenBIO Award awarded for the first time
First Nordic Life Science Days take place
25 measures to strengthen life sciences in Sweden
The three industry organizations LIF, Swedish Medtech and SwedenBIO present a joint action plan for life science. The action plan consists of 25 measures to strengthen Sweden’s competitiveness. The action plan will be revised in 2018.
Read more about how we work to give the life sciences industry a strong voice.
The government forms a collaboration group for life science and SwedenBIO is invited together with ten industry representatives for a close dialog with three ministries.
A guide for disclosure of information on listing is being developed.
An advisory material to help companies find the right minimum level of information to provide about their projects when seeking new capital.
Read our updated industry standard for raising capital in life sciences here.
We will be 250 members
SwedenBIO goes international – Nordic consortium formed
Intensive policy work in the life science office’s thematic groups. Ahead of the release of the life science strategy, etc.
SKR and the life science industry have signed two agreements to develop work on clinical trials and quality registers.
Three comprehensive industry analyses are being produced
What is the financial landscape? What is precision medicine and which companies are developing new drugs and vaccines? Link to reports.
